MicroPort CardioFlow Medtech Corp. (HK:2160) has released an update.
MicroPort CardioFlow Medtech Corporation reported a significant improvement in its financial performance for the first half of 2024, with a 26.5% increase in revenue and a gross profit rise of 35.7% compared to the same period in 2023. These gains are attributed to successful cost reduction strategies, scaling economies, and increased sales in both domestic and international markets, particularly from their TAVI products and newly commercialized cardiac devices. Despite these improvements, the company still recorded a loss for the period, though markedly lower than the previous year.
For further insights into HK:2160 stock, check out TipRanks’ Stock Analysis page.
